Metabolome and metaboproteome remodeling in nuclear reprogramming

Nuclear reprogramming resets differentiated tissue to generate induced pluripotent stem (iPS) cells. While genomic attributes underlying reacquisition of the embryonic-like state have been delineated, less is known regarding the metabolic dynamics underscoring induction of pluripotency. Metabolomic profiling of fibroblasts vs. iPS cells demonstrated nuclear reprogramming-associated induction of glycolysis, realized through augmented utilization of glucose and accumulation of lactate. Real-time assessment unmasked downregulated mitochondrial reserve capacity and ATP turnover correlating with pluripotent induction. Reduction in oxygen consumption and acceleration of extracellular acidification rates represent high-throughput markers of the transition from oxidative to glycolytic metabolism, characterizing stemness acquisition. The bioenergetic transition was supported by proteome remodeling, whereby 441 proteins were altered between fibroblasts and derived iPS cells. Systems analysis revealed overrepresented canonical pathways and interactome-associated biological processes predicting differential metabolic behavior in response to reprogramming stimuli, including upregulation of glycolysis, purine, arginine, proline, ribonucleoside and ribonucleotide metabolism, and biopolymer and macromolecular catabolism, with concomitant downregulation of oxidative phosphorylation, phosphate metabolism regulation, and precursor biosynthesis processes, prioritizing the impact of energy metabolism within the hierarchy of nuclear reprogramming. Thus, metabolome and metaboproteome remodeling is integral for induction of pluripotency, expanding on the genetic and epigenetic requirements for cell fate manipulation.

[1]  J. Menéndez,et al.  The mitochondrial H+-ATP synthase and the lipogenic switch , 2013, Cell cycle.

[2]  G. Daley,et al.  Influence of Threonine Metabolism on S-Adenosylmethionine and Histone Methylation , 2013, Science.

[3]  Jeroen Krijgsveld,et al.  Highly coordinated proteome dynamics during reprogramming of somatic cells to pluripotency. , 2012, Cell reports.

[4]  G. Daley,et al.  Metabolic regulation in pluripotent stem cells during reprogramming and self-renewal. , 2012, Cell stem cell.

[5]  A. Terzic,et al.  Metabolic plasticity in stem cell homeostasis and differentiation. , 2012, Cell stem cell.

[6]  Andre Terzic,et al.  Systems proteomics for translational network medicine. , 2012, Circulation. Cardiovascular genetics.

[7]  J. Menéndez,et al.  Mitochondrial fusion by pharmacological manipulation impedes somatic cell reprogramming to pluripotency: New insight into the role of mitophagy in cell stemness , 2012, Aging.

[8]  M. Teitell,et al.  Measuring energy metabolism in cultured cells, including human pluripotent stem cells and differentiated cells , 2012, Nature Protocols.

[9]  L. Studer,et al.  The expanding role of miR-302–367 in pluripotency and reprogramming , 2012, Cell cycle.

[10]  Andre Terzic,et al.  Energy metabolism plasticity enables stemness programs , 2012, Annals of the New York Academy of Sciences.

[11]  G. Siuzdak,et al.  Innovation: Metabolomics: the apogee of the omics trilogy , 2012, Nature Reviews Molecular Cell Biology.

[12]  George Q. Daley,et al.  Reprogramming Cellular Identity for Regenerative Medicine , 2012, Cell.

[13]  C. López-Otín,et al.  Activation of AMP-activated protein kinase (AMPK) provides a metabolic barrier to reprogramming somatic cells into stem cells , 2012, Cell cycle.

[14]  L. Cantley,et al.  Human pluripotent stem cells decouple respiration from energy production , 2011, The EMBO journal.

[15]  Laurent Vergnes,et al.  UCP2 regulates energy metabolism and differentiation potential of human pluripotent stem cells , 2011, The EMBO journal.

[16]  A. Terzic,et al.  Energy metabolism in nuclear reprogramming. , 2011, Biomarkers in medicine.

[17]  Juan Carlos Izpisua Belmonte,et al.  The metabolome of induced pluripotent stem cells reveals metabolic changes occurring in somatic cell reprogramming , 2011, Cell Research.

[18]  J. Menéndez,et al.  mTOR-regulated senescence and autophagy during reprogramming of somatic cells to pluripotency: A roadmap from energy metabolism to stem cell renewal and aging , 2011, Cell cycle.

[19]  C. Sander,et al.  Genome-wide identification of microRNA targets in human ES cells reveals a role for miR-302 in modulating BMP response. , 2011, Genes & development.

[20]  Hans Lehrach,et al.  Human Induced Pluripotent Stem Cells Harbor Homoplasmic and Heteroplasmic Mitochondrial DNA Mutations While Maintaining Human Embryonic Stem Cell–like Metabolic Reprogramming , 2011, Stem cells.

[21]  Andre Terzic,et al.  Somatic oxidative bioenergetics transitions into pluripotency-dependent glycolysis to facilitate nuclear reprogramming. , 2011, Cell metabolism.

[22]  J. I. Izpisúa Belmonte,et al.  Anaerobicizing into pluripotency. , 2011, Cell metabolism.

[23]  G. Schatten,et al.  Energy Metabolism in Human Pluripotent Stem Cells and Their Differentiated Counterparts , 2011, PloS one.

[24]  Michel Sadelain,et al.  miR-371-3 expression predicts neural differentiation propensity in human pluripotent stem cells. , 2011, Cell stem cell.

[25]  J. Ellis,et al.  iPSC Technology: Platform for Drug Discovery , 2011, Clinical pharmacology and therapeutics.

[26]  Robert L. Judson,et al.  Multiple targets of miR-302 and miR-372 promote reprogramming of human fibroblasts to induced pluripotent stem cells , 2011, Nature Biotechnology.

[27]  I. Sancho-Martinez,et al.  Disease Correction the iPSC Way: Advances in iPSC‐Based Therapy , 2011, Clinical pharmacology and therapeutics.

[28]  Timothy J. Nelson,et al.  Induced Pluripotent Stem Cells: An Emerging Theranostics Platform , 2011, Clinical pharmacology and therapeutics.

[29]  S. Yamanaka,et al.  The Use of Induced Pluripotent Stem Cells in Drug Development , 2011, Clinical pharmacology and therapeutics.

[30]  A. Tsirigos,et al.  Ketones and lactate increase cancer cell “stemness,” driving recurrence, metastasis and poor clinical outcome in breast cancer , 2011, Cell cycle.

[31]  J. Adjaye,et al.  Modulation of mitochondrial biogenesis and bioenergetic metabolism upon in vitro and in vivo differentiation of human ES and iPS cells. , 2010, The International journal of developmental biology.

[32]  Sheng Ding,et al.  Reprogramming of human primary somatic cells by OCT4 and chemical compounds. , 2010, Cell stem cell.

[33]  Andre Terzic,et al.  Induced pluripotent stem cells: developmental biology to regenerative medicine , 2010, Nature Reviews Cardiology.

[34]  Mark Ellisman,et al.  Mitochondrial Rejuvenation After Induced Pluripotency , 2010, PloS one.

[35]  Alfredo Quiñones-Hinojosa,et al.  Oxygen in stem cell biology: a critical component of the stem cell niche. , 2010, Cell stem cell.

[36]  D. K. Arrell,et al.  ATP‐Sensitive K+ Channel‐Deficient Dilated Cardiomyopathy Proteome Remodeled by Embryonic Stem Cell Therapy , 2010, Stem cells.

[37]  H. Schöler,et al.  Induced pluripotent stem cells at nanoscale. , 2010, Stem cells and development.

[38]  M. Stojkovic,et al.  Human Induced Pluripotent Stem Cell Lines Show Stress Defense Mechanisms and Mitochondrial Regulation Similar to Those of Human Embryonic Stem Cells , 2010, Stem cells.

[39]  Hans Lehrach,et al.  The Senescence‐Related Mitochondrial/Oxidative Stress Pathway is Repressed in Human Induced Pluripotent Stem Cells , 2010, Stem cells.

[40]  C. Pereira,et al.  Senescence impairs successful reprogramming to pluripotent stem cells. , 2009, Genes & development.

[41]  T. Ichisaka,et al.  Hypoxia enhances the generation of induced pluripotent stem cells. , 2009, Cell stem cell.

[42]  T. Ichisaka,et al.  Suppression of induced pluripotent stem cell generation by the p53–p21 pathway , 2009, Nature.

[43]  Manuel Serrano,et al.  A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity , 2009, Nature.

[44]  M. Blasco,et al.  The Ink4/Arf locus is a barrier for iPS cell reprogramming , 2009, Nature.

[45]  Timothy J. Nelson,et al.  Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells. , 2009, Circulation.

[46]  G. Stein,et al.  Pluripotency: Toward a gold standard for human ES and iPS cells , 2009, Journal of cellular physiology.

[47]  Peter W Zandstra,et al.  Alternative induced pluripotent stem cell characterization criteria for in vitro applications. , 2009, Cell stem cell.

[48]  Shinya Yamanaka,et al.  Broader implications of defining standards for the pluripotency of iPSCs. , 2009, Cell stem cell.

[49]  L. Fink,et al.  Phenotypic correction of murine hemophilia A using an iPS cell-based therapy , 2009, Proceedings of the National Academy of Sciences.

[50]  K. Hochedlinger,et al.  Guidelines and techniques for the generation of induced pluripotent stem cells. , 2008, Cell stem cell.

[51]  Ryan B. Huang,et al.  Effects of oxygen on mouse embryonic stem cell growth, phenotype retention, and cellular energetics. , 2008, Biotechnology and bioengineering.

[52]  R. Roberts,et al.  Identification of oxygen-sensitive transcriptional programs in human embryonic stem cells. , 2008, Stem cells and development.

[53]  R. Jaenisch,et al.  Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease , 2008, Proceedings of the National Academy of Sciences.

[54]  O. Lee,et al.  Coordinated Changes of Mitochondrial Biogenesis and Antioxidant Enzymes During Osteogenic Differentiation of Human Mesenchymal Stem Cells , 2008, Stem cells.

[55]  D. K. Arrell,et al.  Cardioinductive Network Guiding Stem Cell Differentiation Revealed by Proteomic Cartography of Tumor Necrosis Factor α‐Primed Endodermal Secretome , 2008, Stem cells.

[56]  Fidel Ramírez,et al.  Computing topological parameters of biological networks , 2008, Bioinform..

[57]  Marius Wernig,et al.  Treatment of Sickle Cell Anemia Mouse Model with iPS Cells Generated from Autologous Skin , 2007, Science.

[58]  B. Bavister,et al.  Mitochondria in stem cells. , 2007, Mitochondrion.

[59]  D. K. Arrell,et al.  Cardiopoietic programming of embryonic stem cells for tumor-free heart repair , 2007, The Journal of experimental medicine.

[60]  Andre Terzic,et al.  Mitochondrial oxidative metabolism is required for the cardiac differentiation of stem cells , 2007, Nature Clinical Practice Cardiovascular Medicine.

[61]  Eyal Gottlieb,et al.  TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis , 2006, Cell.

[62]  A. Tabilio,et al.  Characterization of Mitochondrial and Extra-mitochondrial Oxygen Consuming Reactions in Human Hematopoietic Stem Cells , 2005, Journal of Biological Chemistry.

[63]  R. Roberts,et al.  Low O2 tensions and the prevention of differentiation of hES cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[64]  R. Albert,et al.  The large-scale organization of metabolic networks , 2000, Nature.

[65]  D. N. Perkins,et al.  Probability‐based protein identification by searching sequence databases using mass spectrometry data , 1999, Electrophoresis.

[66]  J. Lindon,et al.  'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[67]  Albert,et al.  Emergence of scaling in random networks , 1999, Science.

[68]  O. Fiehn Metabolomics – the link between genotypes and phenotypes , 2004, Plant Molecular Biology.